SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: boronate6/16/2005 12:28:33 PM
   of 3044
 
Angela Dispenzieri at the Mayo clinics wrote an accompanying editorial in the same NJM issue that published the APEX data. the title of the editorial is "Much Ado About Something". She points out some of the caveats that limited interpretation of the trial results as well as the sobering fact that a 9-month cost of Velcade (the maximum treatment course in the APEX trial although the average use was 4.5 months) is about 47,000 dollars as opposed to 170 dollars for Dex. She, however, concluded more positively by:

"So where does this leave us? The take-home message of the APEX study is that bortezomib is an effective therapy against relapsed myeloma, a fact to which anyone who has used the drug can attest. It is a much-needed additional tool against this devastating disease. Though other drugs have similar
overall response rates as monotherapy, aside from high-dose melphalan, no other single agent has resulted in complete response rates of 6 percent in patients with the relapsed or refractory disease. Moreover, bortezomib markedly enhances the sensitivity of myeloma cells to other chemotherapeutic
agents both in vitro and in vivo. At this year’s meeting of the American Society of Hematology, there were many preliminary reports of high rates of response to bortezomib, given either as a single agent or in combination with other agents — including dexamethasone, melphalan, doxorubicin, and
thalidomide — and radiation."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News